Hit enter to search or ESC to close
Immuneering Corporation
  • ABOUT
    • Our Approach
    • Team
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
  • ABOUT
    • Our Approach
    • Team
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
All Posts By

immun-ops2020

immun-ops2020 In News

The Dementia Discovery Fund and Immuneering announce a Research Collaboration to identify novel drug targets and drug candidates for Alzheimer’s disease

Cambridge, MA and London, 18 June 2018 – The Dementia Discovery Fund (“DDF”) and Immuneering Corporation (“Immuneering”) today announce they have entered into a joint research collaboration to identify novel drug targets…

Read More
immun-ops2020 In News

Immuneering CEO Ben Zeskind to speak at 4th Cancer Cachexia Conference

June 11th, 2018 — Immuneering’s CEO (Ben Zeskind) is scheduled to present an invited talk entitled “Data-driven identification and optimization of new medicines for cancer cachexia” at the 4th Cancer…

Read More
immun-ops2020 In Publications

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone

For more than 20 years, Copaxone (glatiramer acetate, Teva), a non-biological complex drug, has been a safe and effective treatment option for multiple sclerosis. In 2016, a follow-on glatiramer acetate…

Read More
immun-ops2020 In Publications

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

Huntington Disease (HD) is an incurable autosomal dominant neurodegenerative disorder driven by an expansion repeat giving rise to the mutant huntingtin protein (mHtt), which is known to disrupt a multitude…

Read More
immun-ops2020 In Publications

Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated through Molecular Dynamics Simulations

When a small molecule binds to the androgen receptor (AR), a conformational change can occur which impacts subsequent binding of co-regulator proteins and DNA. In order to accurately study this…

Read More
immun-ops2020 In Publications

Metastasis: Leveraging transcriptomics to identify potential therapeutics

Five-year survival rates for patients whose cancer has metastasized are dramatically lower than for those with localized disease. However, few therapeutic development efforts specifically focus on inhibiting the process of…

Read More
immun-ops2020 In Publications

Cachexia: Leveraging transcriptomics to identify potential therapeutics

Cachexia is a common cause of morbidity across multiple cancer types, yet remains largely under-studied especially in the realm of transcriptomics. An essential component of cancer cachexia is the induced…

Read More
immun-ops2020 In Publications

Loss of the Sigma-1 receptor disrupts pridopidine-induced gene expression

Objective: Investigate the role of S1R in the mechanism of action of pridopidine. Background: Sigma-1 receptor (S1R) is an ER chaperone protein involved in neuromodulation and neuroplasticity. Pridopidine is a…

Read More
immun-ops2020 In Publications

Integrity, standards, and QC-related issues with big-data in pre-clinical drug discovery

The tremendous expansion of data analytics and public and private big datasets presents an important opportunity for pre-clinical drug discovery and development. In the field of life sciences, the growth…

Read More
immun-ops2020 In Publications

A meta-metastasis analysis identifies pan-cancer markers and therapeutic targets

Metastasis is a leading cause of cancer-associated deaths across several cancer types, yet the molecular details of its development have not been fully elucidated. Transcriptomic analysis can provide insight into…

Read More
Previous 1 … 5 6 7 8 9 … 13 Next
Immuneering logo
  • ABOUT
  • PLATFORM
  • PIPELINE
  • PUBLICATIONS
  • FOR INVESTORS
  • CONTACT
  • Terms of Use
  • Privacy Policy

© 2025 Immuneering Corporation.